# SUNRAY-01 (NCT06119581)

> A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06119581
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Eli Lilly and Company
- Conditions: Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis
- Interventions: LY3537982; Pembrolizumab; Placebo; Cisplatin; Carboplatin; Pemetrexed
- Enrollment: 1264
- Primary outcome: Dose Optimization and Safety Lead-In Part B: Number of Participants with a Treatment Emergent Adverse Event(s) (TEAE)
- Primary outcome: Part A and Part B: Progression-Free Survival (PFS)

## Commentary we found

- X threads: 3
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=sunray-01-nct06119581